Overcoming the RNA therapeutics delivery challenge

Nucleic acid-based therapeutics have potential in treating a range of diseases, but they can be challenging to deliver to intended sites in the body. While lipid nanoparticles (LNPs) have emerged as a powerful tool for delivery, therapeutic applications have been predominantly limited to liver indications. Find out how Liberate Bio is advancing the development of next-generation LNP delivery systems aimed at tissue-specific targeting of nucleic acid therapeutics beyond the liver. Discover how the protein barcoding application on the Quantum-Si Platinum^® Next-Generation Protein Sequencer™ is helping Liberate Bio achieve this goal.